Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Matthew Macaluso
Professor
Close
E-mail
macaluso@uab.edu
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Matthew Macaluso
Professor
Positions
Senior Scientist (C)
,
Center for Clinical and Translational Science (CCTS)
,
General Clinical Research Center
Senior Scientist (C)
,
Comprehensive Neuroscience Center
,
General Clinical Research Center
Professor (P)
,
Psychiatry - Behavioral Neurobiology
,
Psychiatry
Vice Chair of Clinical Affairs
,
Psychiatry - Behavioral Neurobiology
,
Psychiatry
Publications
Research
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2022
Challenges of Assessing Resident Competency in Well-Being: Development of the Psychiatry Milestones 2.0 Well-Being Subcompetency
.
Academic Medicine
. 97:351-356.
2022
2021
Psychiatry Milestones 2.0: Using the Supplemental Guide to Create a Shared Model of the Development of Professional Identity and Expertise
.
Academic Psychiatry
. 45:500-505.
2021
2021
Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset
.
Journal of Clinical Psychiatry
. 82.
2021
2021
Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial
2021
2021
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression
.
Psychiatry Research
. 296.
2021
2021
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression
.
Annals of Clinical Psychiatry
. 33:18-26.
2021
2020
Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression
.
American Journal of Geriatric Psychiatry
. 28:933-945.
2020
2020
Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder
.
Psychiatry Research
. 290.
2020
2020
150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression
2020
2019
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial
.
BMC Psychiatry
. 19.
2019
2019
Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies
.
Journal of Psychiatric Research
. 114:211-213.
2019
2019
Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
.
Journal of Psychiatric Research
. 111:59-67.
2019
2019
Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial
.
Journal of Clinical Psychiatry
. 80.
2019
2015
How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.
.
The primary care companion for CNS disorders
. 17.
2015
2014
Secondary psychosis 3 months prior to the overt symptoms of multiple myeloma: a case report.
.
The primary care companion for CNS disorders
. 16.
2014
2012
How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression.
.
Journal of Psychiatric Practice
. 18:281-286.
2012
2012
How biomarkers will change psychiatry: from clinical trials to practice. Part I: introduction.
.
Journal of Psychiatric Practice
. 18:118-121.
2012
2011
Phase I trials: from traditional to newer approaches part II.
.
Journal of Psychiatric Practice
. 17:277-284.
2011
2011
Phase I trials: from traditional to newer approaches. Part I.
.
Journal of Psychiatric Practice
. 17:200-203.
2011
2011
CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?
.
Journal of Clinical Psychopharmacology
. 31:143-145.
2011
2010
The Role of Benzodiazepines in the Treatment of Anxiety Disorders: A Clinical Review
.
Psychiatric Annals
. 40:605-610.
2010
2010
The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
.
Journal of Psychiatric Practice
. 16:289-296.
2010
2010
Twenty percent of a representative sample of patients taking bupropion have abnormal, asymptomatic electroencephalographic findings.
.
Journal of Clinical Psychopharmacology
. 30:312-317.
2010
2009
Duloxetine for the treatment of generalized anxiety disorder: a review.
.
Neuropsychiatric Disease and Treatment
. 5:23-31.
2009
2008
A 19-year-old Black Woman with Psychotic and Depressive Symptoms
.
Psychiatric Annals
. 38.
2008
2000
Alaninyltryptophan hydrate, glycyltryptophan dihydrate and tryptophylglycine hydrate
.
Acta Crystallographica Section C: Crystal Structure Communications
. 56:e469-e471.
2000
Chapter
Filter
Year
Title
Altmetric
2012
Phase I Trials
2012
Research
Principal Investigator On
A Feasibility Trial of Esketamine Plus Cognitive Behavioral Therapy for Patients with Major Depressive Disorder Who are Hospitalized for Suicidal Ideation
awarded by
Yale University
Private Grant
awarded by
LIVANOVA USA, INC.
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
Private Grant
awarded by
AVANIR PHARMACEUTICALS, INC.
Private Grant
awarded by
NOVARTIS PHARMACEUTICALS CORPORATION
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
LIVANOVA USA, INC.
Private Grant
awarded by
NEUROCRINE BIOSCIENCES INC
Private Grant
awarded by
MERCK SHARP & DOHME CORP
Private Grant
awarded by
NEUROCRINE BIOSCIENCES INC
Investigator On
Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders with Treatment Resistant Depression (ASCERTAIN-TRD)
awarded by
PARTNERS HEALTHCARE
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC
Private Grant
awarded by
NEURORX
Private Grant
awarded by
NEURORX
Rural Practice Engagement in Project ECHO (Extension for Community Healthcare Outcomes) Depression
awarded by
ALABAMA DEPARTMENT OF PUBLIC HEALTH
Background
Education And Training
Doctor of Osteopathy in Osteopathic Medicine / Osteopathy,
University of Medicine and Denistry of New Jersey
2005
Bachelor of Arts in Chemistry,
Rutgers University : Newark
2001
Contact
Full Name
Matthew
Macaluso